Trial Profile
A study of ibrutinib and acalabrutinib in patients with follicular lymphoma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Jan 2017
Price :
$35
*
At a glance
- Drugs Acalabrutinib (Primary) ; Ibrutinib (Primary)
- Indications Follicular lymphoma
- Focus Therapeutic Use
- 24 Jan 2017 New trial record
- 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.